Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2012; 18(48): 7242-7250
Published online Dec 28, 2012. doi: 10.3748/wjg.v18.i48.7242
Published online Dec 28, 2012. doi: 10.3748/wjg.v18.i48.7242
Author | Year | Treatment | HCC stage | AFP change level (%) | No. of patients | ||
Study size (n = 974) | M/F (776/198) | AFP response (n = 463) | |||||
Chen et al[21] | 2005 | Sys/thalidomide | I-III | 50 | 42 | 33/9 | 10 (23.8%) |
Chan et al[20] | 2009 | Sys/doxorubicin or PIAF | I-III | 20 | 117 | 104/13 | 47 (40.2%) |
Riaz et al[27] | 2009 | Loc/chemoembolization or radioembolization | I-IV | 50 | 125 | 91/34 | 81 (64.8%) |
Vora et al[29] | 2009 | Sys/five systemic regimens | I-III | 50 | 107 | 78/29 | 18 (16.8%) |
Shao et al[28] | 2010 | Sys/Antiantiogenic agents | I-II | 20 | 72 | 65/7 | 12 (16.7%) |
Kim et al[23] | 2011 | Loc/chemoradiotherapy | III-IV | 50 | 149 | 127/22 | 101 (67.8%) |
Yau et al[30] | 2011 | Sys/sorafenib | II-IV | 20 | 41 | 36/5 | 9 (21.9%) |
Kao et al[22] | 2012 | Loc/radiofrequency ablation | I-III | 20 | 58 | 34/24 | 46 (79.3%) |
Lee et al[24] | 2012/H | Loc/HAIC | III-IV | 20 | 60 | 49/11 | 25 (41.7%) |
Lee et al[24] | 2012/C | Loc/CCRT | III-IV | 20 | 67 | 55/12 | 52 (77.6%) |
Memon et al[25] | 2012 | Loc/transarterialtherapy | I-III | 50 | 51 | 30/21 | 30 (58.8%) |
Personeni et al[26] | 2012 | Sys/sorafenib | I-III | 20 | 85 | 74/11 | 32 (37.6%) |
- Citation: Xu XS, Qu K, Liu C, Zhang YL, Liu J, Song YZ, Zhang P, Liu SN, Chang HL. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol 2012; 18(48): 7242-7250
- URL: https://www.wjgnet.com/1007-9327/full/v18/i48/7242.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i48.7242